One of the first studies to investigate the prevalence of unrecognized cognitive impairment among patients seen at Federally Qualified Health Centers, has found that it is ubiquitous, especially among minoritized older adults. These facilities provide primary care and preventive services regardless of ability to pay or health insurance status to more than 30 million patients, including a growing number of older adults.

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial are among the highlights. Results from the E1910 trial led to an FDA approval in June 2024 after it found that adding the immunotherapy drug blinatumomab to standard front-line consolidation chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival.